Trials Articles

Articles
Subclinical Coronary Atherosclerosis and Risk for Myocardial Infarction in a Danish Cohort: A Prospective Observational Cohort Study
Fuchs A, Kühl JT, Sigvardsen PE, et al.
Journal:
Ann Intern Med

First published: March 23, 2023 DOI: 10.7326/M22-3027
View
- Share
Articles
Generalizability of the REDUCE-IT trial to South Asians with cardiovascular disease
Krishnaraj A, Bakbak E, Teoh H, et al.
Journal:
Med (N Y)

First published: January 10, 2023 DOI: 10.1016/j.medj.2022.12.008
View
- Share
Articles
Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial
Ray KK, Troquay RPT, Visseren FLJ, et al.
Journal:
Lancet Diabetes Endocrinol

First published: January 5, 2023 DOI: 10.1016/S2213-8587(22)00353-9
View
- Share
Articles
The year in cardiovascular medicine 2022: the top 10 papers in dyslipidaemias
Tokgozoglu L, Orringer C, Catapano A
Journal:
Eur Heart J

First published: January 2, 2023 DOI: 10.1093/eurheartj/ehac750
View
- Share
Articles
GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes
Marx N, Husain M, Lehrke M, et al.
Journal:
Circulation

First published: December 12, 2022 DOI: 10.1161/CIRCULATIONAHA.122.059595
View
- Share
Articles
Effects of routine early treatment with PCSK9 inhibitors in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a randomised, double-blind, sham-controlled trial
Mehta SR, Pare G, Lonn EM, et al.
Journal:
EuroIntervention

First published: December 2, 2022 DOI: 10.4244/EIJ-D-22-00735
View
- Share
Articles
Early initiation of PCSK9 inhibition in myocardial infarction could be EPIC for patient care
Bhatt DL
Journal:
EuroIntervention

First published: December 2, 2022 DOI: 10.4244/EIJ-E-22-00047
View
- Share
Articles
Effect of inclisiran on lipids in primary prevention: the ORION-11 trial
Ray KK, Kallend D, Leiter LA, et al.
Journal:
Eur Heart J

First published: November 4, 2022 DOI: 10.1093/eurheartj/ehac615
View
- Share
Articles
Inclisiran and cardiovascular events: a patient-level analysis of phase III trials
Ray KK, Raal FJ, Kallend DG, et al.
Journal:
Eur Heart J

First published: November 4, 2022 DOI: 10.1093/eurheartj/ehac594
View
- Share
Articles
EPA Versus Mixed EPA/DHA Plus Statin for Coronary Atherosclerosis: Meta-Analysis of Prospective Imaging Trials
Sheppard JP, Lakshmanan S, Dahal S, et al.
Journal:
JACC Cardiovasc Imaging

First published: October 15, 2022 DOI: 10.1016/j.jcmg.2022.04.014
View
- Share

Trials Articles

Articles

Subclinical Coronary Atherosclerosis and Risk for Myocardial Infarction in a Danish Cohort: A Prospective Observational Cohort Study

Fuchs A, Kühl JT, Sigvardsen PE, et al.

Articles

Generalizability of the REDUCE-IT trial to South Asians with cardiovascular disease

Krishnaraj A, Bakbak E, Teoh H, et al.

Articles

Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial

Ray KK, Troquay RPT, Visseren FLJ, et al.

Articles

The year in cardiovascular medicine 2022: the top 10 papers in dyslipidaemias

Tokgozoglu L, Orringer C, Catapano A

Articles

GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes

Marx N, Husain M, Lehrke M, et al.

Articles

Effects of routine early treatment with PCSK9 inhibitors in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a randomised, double-blind, sham-controlled trial

Mehta SR, Pare G, Lonn EM, et al.

Articles

Early initiation of PCSK9 inhibition in myocardial infarction could be EPIC for patient care

Bhatt DL

Articles

Effect of inclisiran on lipids in primary prevention: the ORION-11 trial

Ray KK, Kallend D, Leiter LA, et al.

Articles

Inclisiran and cardiovascular events: a patient-level analysis of phase III trials

Ray KK, Raal FJ, Kallend DG, et al.

Articles

EPA Versus Mixed EPA/DHA Plus Statin for Coronary Atherosclerosis: Meta-Analysis of Prospective Imaging Trials

Sheppard JP, Lakshmanan S, Dahal S, et al.

Articles

Subclinical Coronary Atherosclerosis and Risk for Myocardial Infarction in a Danish Cohort: A Prospective Observational Cohort Study

Fuchs A, Kühl JT, Sigvardsen PE, et al.

Share

Articles

Generalizability of the REDUCE-IT trial to South Asians with cardiovascular disease

Krishnaraj A, Bakbak E, Teoh H, et al.

Share

Articles

Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial

Ray KK, Troquay RPT, Visseren FLJ, et al.

Share

Articles

The year in cardiovascular medicine 2022: the top 10 papers in dyslipidaemias

Tokgozoglu L, Orringer C, Catapano A

Share

Articles

GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes

Marx N, Husain M, Lehrke M, et al.

Share

Articles

Effects of routine early treatment with PCSK9 inhibitors in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a randomised, double-blind, sham-controlled trial

Mehta SR, Pare G, Lonn EM, et al.

Share

Articles

Early initiation of PCSK9 inhibition in myocardial infarction could be EPIC for patient care

Bhatt DL

Share

Articles

Effect of inclisiran on lipids in primary prevention: the ORION-11 trial

Ray KK, Kallend D, Leiter LA, et al.

Share

Articles

Inclisiran and cardiovascular events: a patient-level analysis of phase III trials

Ray KK, Raal FJ, Kallend DG, et al.

Share

Articles

EPA Versus Mixed EPA/DHA Plus Statin for Coronary Atherosclerosis: Meta-Analysis of Prospective Imaging Trials

Sheppard JP, Lakshmanan S, Dahal S, et al.

Share